IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days Anticipate significant U.S. orders to follow FDA marketing authorization Encouraging dialogue with FDA supports expected authorization later in 2026 NASHVILLE, Tenn.